GSK’s Shingrix Strategy Shift Drives Sales Beat Even as Vaccines Slow

Why It Matters

The shift to target comorbid patients revived Shingrix growth, offsetting a broader vaccine market slowdown and underscoring the importance of strategic segmentation in a skeptical U.S. environment.

Key Takeaways

• Shingrix sales rose 20% to $1.4 billion in Q1 2025.
• European uptake surged 51% YoY, driving most growth.
• U.S. Shingrix revenue increased 12% despite vaccine skepticism.
• GSK’s other vaccines fell 9% overall in Q1.
• GSK halted XMT‑2056 cancer program after $100 million upfront.

Pulse Analysis

GSK’s decision to pivot Shingrix toward patients with comorbid conditions paid immediate dividends, delivering a 20% sales lift that outpaced consensus estimates. By emphasizing higher‑risk groups such as diabetics and heart‑disease patients, the company tapped a segment less sensitive to the current anti‑vaccine sentiment, especially in the United States where policy changes have constrained access. This targeted approach not only rescued Shingrix’s growth trajectory but also reinforced the broader lesson that nuanced market segmentation can counteract macro‑level headwinds in the vaccine space.

The broader vaccine portfolio, however, tells a different story. GSK’s flu shot contributed a modest $13.5 million, while its RSV candidate Arexvy and meningitis vaccine slipped 18% and 3% respectively, reflecting a 9% decline across all other pediatric and adult vaccines. The downturn aligns with rising vaccine skepticism fueled by high‑profile political figures, which has eroded public confidence and complicated distribution channels. Competitors like Pfizer echo similar concerns, noting that the discourse around vaccines has become almost religious, further dampening demand for non‑essential immunizations.

Looking ahead, GSK’s mixed results highlight both resilience and vulnerability. The strong performance of specialty medicines—particularly the HIV pill Dovato and asthma biologic Nucala—provides a buffer against vaccine volatility. Yet the company’s decision to discontinue the XMT‑2056 STING agonist, after a $100 million upfront investment, signals a tightening of its oncology pipeline amid uncertain returns. Investors will watch whether GSK can replicate Shingrix’s targeted success across other products while navigating a politically charged U.S. market.